1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Fermentalg

Fermentalg

ALGAE.PA
Fermentalgundefined flagEuronext Paris
0.50
EUR
+0.00
- -
47.99MMarket Cap
Fermentalg
ALGAE.PA
(Euronext Paris)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.02
0.02
0.02
0.09
0.04
0.01
0.01
0.01
0.11
0.1
0.16
0.18
0.09
0.15
0.13
Revenue per Share
-0.12
-0.3
-0.23
-0.4
-0.42
-0.63
-0.56
-0.47
-0.97
-0.32
-0.19
-0.24
-0.32
-0.17
-0.09
Basic EPS, GAAP
-0.36
-0.36
-0.99
-0.65
-1.14
-1.06
-0.83
-0.53
-0.56
-0.57
-0.33
-0.32
-0.25
-0.03
-0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.1
-0.28
-0.19
-0.35
-0.38
-0.59
-0.51
-0.44
-0.93
-0.27
-0.14
-0.19
-0.27
-0.12
-0.05
Book Value per Share
0.8
0.43
1.68
4.5
3.21
2.53
2.56
1.36
0.57
0.48
0.96
0.67
0.36
0.24
0.1
Tangible Book Value per Share
8
8
8
10
12
12
13
17
18
22
36
41
44
74
105
Basic Weighted Avg Shares
- -
- -
- -
1
- -
- -
- -
- -
2
2
6
8
4
11
13
Sales/Revenue/Turnover
-1,207.86
-2,004.35
-1,513.81
-441.78
-1,207.72
-4,456.93
-4,270
-3,037.4
-479.61
-403.54
-150.17
-115.94
-272.94
-80.47
-70.11
Operating Margin (%)
- -
- -
1
1
1
2
2
3
7
1
1
3
3
3
3
Depreciation Expense
-1
-2
-2
-4
-5
-8
-7
-8
-17
-7
-7
-10
-14
-13
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-661.43
-1,670.29
-969.61
-449.89
-1,103.97
-5,517.52
-4,275.88
-3,289.02
-916.05
-311.93
-121.3
-129.11
-348.73
-111.99
-70.51
Profit Margin (%)
3
-1
7
40
27
13
21
12
4
8
29
22
17
16
7
Working Capital
- -
1
1
2
3
3
8
8
7
11
9
10
14
7
4
LT Debt
6
4
15
49
44
37
41
34
19
20
47
42
31
33
25
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.91%
15.47%
-23.14%
Free Cash Flow
20.77%
43.19%
306.05%
Net Income, GAAP
15.53%
10.27%
-26.71%
Sales/Revenue/Turnover
102.6%
68.88%
16.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
13

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.32
2024
- -
- -
- -
- -
-0.17
2025
- -
- -
- -
- -
-0.09

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Astria Therapeutics, Inc. (ATXS)
Living Cell Technologies Limited (LVCLY)
Aspire Biopharma Holdings, Inc. (ASBPW)
Oncopeptides AB (publ) (ONPPF)
tella, Inc. (2191.T)
Oncolys BioPharma Inc. (4588.T)
Business
Fermentalg is a biotechnology company specialized in the development and production of natural microalgae-based products. The company manufactures and sells a broad range of solutions including microalgae biomass, oils, proteins, and nutritional ingredients targeting sectors such as human nutrition, animal feed, aquaculture, cosmetics, and bioactive compounds. Its product portfolio comprises bioactive molecules for immune health and anti-inflammatory applications; natural pigments like astaxanthin and beta-carotene; omega-3 fatty acids; and tailored microalgae strains for customized applications. Founded in 2009 and headquartered in Libourne, France, Fermentalg operates primarily in Europe with expanding global ambitions. The company focuses on the sustainable production of microalgae through proprietary fermentation and photobioreactor technologies. In the last two years, Fermentalg has pursued strategic developments including new partnerships with industry stakeholders to expand market presence and advance its technology platforms. It also undertook operational enhancements to scale up production capacities and recently launched novel product lines in the nutritional supplement category to diversify its offerings. These initiatives reflect Fermentalg’s commitment to innovation and growth in the bio-based industrial segment. Fermentalg serves diverse markets including food and beverages, dietary supplements, pharmaceuticals, and personal care, positioning itself as a key player in the green biotech and sustainable ingredients industry. It operates through direct sales and collaborations with industrial partners and research institutions to drive product development and commercialization. Overall, Fermentalg integrates pioneering microalgae biotechnology with a strategic focus on market-driven products and scalable production processes, underpinned by its headquarters in France and established since 2009.